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Abstract. Previous studies have shown that metalloproteinases (MMPs) participate in the clearance of amyloid- (A) in
Alzheimer’s disease (AD); MMP2 and MMP3 cleave soluble A, and both MMP9 and MT1-MMP are able to degrade soluble
and fibrillar forms of A. The present study shows increased expression levels of active MMP2 in the entorhinal cortex at
early stages of AD-related pathology (Braak and Braak stages I/II-0 and III/IV-A) as revealed by western blotting and gelatin
zymography. Confocal microscopy discloses co-localization of MMP2 and phospho-tau in neurofibrillary tangles and dystrophic
neurites. MMP2 has the capacity to cleave recombinant tau in vitro in a dose-dependent manner, consistent with a physiological
function of MMP2 in normal tau proteolysis. However, MMP2 does not cleave hyperphosphorylated and dephosphorylated
tau from enriched paired helical filament fractions. These observations raise the possibility that accumulation of MMP2 in
neurofibrillary tangles and concomitant loss of proteolytic capacity on tau protein is a response geared to eliminating production
of toxic truncated tau species in AD brains.
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INTRODUCTION
Alzheimer’s disease (AD) is a progressive neu-
rodegenerative disease causing loss of neurons and
neuronal connectivity in several brain regions. In addi-
tion, multiple metabolic pathways are altered in the
course of the degenerative process [1, 2]. AD is a
long-lasting biological process in which neurofibril-
lary tangles (NFTs) progress from the entorhinal and
transentorhinal cortex (stages I and II), hippocam-
pus and limbic system (stages III and IV), and the
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whole neocortex (V and VI), whereas the progress of
amyloid- (A) plaques follows a different regional
pattern with increasing A plaque burden in the whole
brain [3].
The metabolism of A production and clearance,
and hyperphosphorylation of tau, are very complex and
involve several mechanisms, some leading to the for-
mation of oligomeric and fibrillar species and truncated
products which are toxic to nerve cells [4, 5].
A growing body of evidence indicates that matrix
metalloproteinases (MMPs) may play an important
role in the pathogenesis of AD and other neurode-
generative pathologies. MMPs, collectively called
matrixins, are a family of zinc and calcium enzymes
that are able to digest components of the extracellular
matrix such as collagen, proteoglycan, and laminin [6].
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The distribution of the MMPs in the central nervous
system is widespread; they are secreted by neurons,
oligodendrocytes, microglia, and endothelial cells [7].
MMPs participate in the clearance of A in AD [8–11].
In particular, growing data point to MMP2 (gelatinase
A) and MMP9 (gelatinase B) as important players in
the metabolism of A. Upregulation of MMP2 and
MMP9 is induced by A in mixed primary culture
[12, 13]. APP/PS1 transgenic mice have increased
levels of MMP2 and MMP9 in astrocytes around A
plaques; and treatment with the MMP inhibitor GM-
6001 increases A levels in brain interstitial fluid in
these transgenic mice [14]. Although most evidence on
the role of MMPs in AD points to advanced cases of the
disease, some data indicate that deregulation of met-
alloproteinases may also occur at early stages of AD
[15]. Recent studies clearly demonstrated the upregu-
lation of MMP2 and MMP9 in the hippocampus of the
5xFAD mouse model of AD during the asymptomatic
and initial stage of the pathology [16].
We hypothesized that MMP2 and MMP9 may par-
ticipate in the normal metabolism of other proteins
involved in AD, in addition to A, and particularly
in tau metabolism. Recently, it has been shown that
limited cleavage by MMP9 enhances the formation of
tau oligomers [17]. Furthermore, we speculated that
the effects of MMP deregulation at early stages of
AD-related pathology may have implications in tau
proteolysis. Therefore, in this study, we started investi-
gating modifications in the expression and localization
of MMP2 in the entorhinal cortex in normal middle-
aged individuals with no AD-related pathology and
in cases with early stages of AD-related pathology
mainly consistent with the presence of NFTs. Func-
tional studies assessing the capacity of MMP2 to cleave
recombinant tau, along with hyperphosphorylated and
dephosphorylated tau aggregates extracted from cor-
tex of AD, were carried out to increase understanding
of the contribution of MMP2 in tau metabolism.
MATERIALS AND METHODS
Tissue samples
The selection of cases examined in the present study
corresponded to a consecutive series of brain dona-
tions of patients dying from unrelated causes at a
general hospital. The postmortem delay between death
and processing was between 4 and 6.30 h. Cases with
neurological symptoms and signs, hepatic or renal
function impairment, hypoxia, infection, autoimmune
disorders, disseminated neoplasia, or prolonged agonic
state were excluded. The clinical records in all cases
with AD-related pathology were re-assessed by phone
calls or interviews with relatives asking about any neu-
rological or cognitive change. Therefore, all cases with
AD-related pathology were considered possible pre-
clinical stages. At autopsy, half of each brain was fixed
in formalin, while the other half was cut in coronal
sections 1 cm thick, and selected brain regions were
dissected, collected, and numbered in plastic bags,
frozen on dry ice, and stored at −80◦C until use. For
diagnostic morphological studies, the brains were fixed
by immersion in 4% buffered formalin for 2 or 3 weeks.
The tissue was embedded in paraffin, and de-waxed
sections, 5 m thick, were processed for neuropatho-
logical study. Staging of AD-related pathology was
carried out following Braak and Braak criteria [3],
adapted to paraffin sections [18]. Cases with additional
pathology (either tau, i.e., grains; -synuclein: Lewy
bodies in other brain regions; TDP-43 pathology; or
vascular in any area) were excluded. Special care was
also taken to minimize the amount of A plaques in
the present series to increase the weight of tau pathol-
ogy. Following these conditions, the following cases
were used in the present study: middle-aged subjects
with no neuropathological lesions (MA): 9 (8 men, 1
women; age: 53.6 ± 9.3), AD-related pathology stages
I/II-0:7 (3 men, 4 women; age: 66 ± 7.5), and AD-
related pathology stages III/IV-A: 8 (4 men, 4 women,
age: 79 ± 5.3). Studies were focused on the entorhinal
cortex.
Preparation of samples
80 mg of entorhinal cortex from MA, ADI/II-0,
and ADIII/IV-A cases was homogenized in 800 l of
Ripa buffer (50 mM Tris HCl pH 8; 150 mM NaCl,
1% NP-40; 0.5% sodium deoxycholate; 0.1% SDS)
plus 1 mM phenylmethylsulfonyl fluoride (PMSF) and
protease inhibitor tablets (Roche Molecular Systems,
Barcelona, Spain). The samples were then centrifuged
at 10,000 × g for 10 min and the total protein of
the supernatant was quantified with the BCA (bicin-
choninic acid) assay (Biorad, CA, USA).
Western blot
20 g of total protein was run in SDS-PAGE
using 8% acrylamide gel and then transferred to
a nitrocellulose membrane for 2 h at 200 mA. The
membrane was then blocked with 5% skimmed milk
for 1 h prior to overnight incubation at 4◦C with
anti-MMP2 monoclonal antibody (Millipore-Merck,
Barcelona, Spain) at a dilution of 1:1,000. The blots
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were then incubated for 2 h at room temperature
with anti-mouse horseradish conjugated secondary
antibody (DAKO, Barcelona, Spain) and visualized
with the ECL chemiluminescence method (Amersham,
Barcelona, Spain). The monoclonal anti--actin anti-
body (Sigma-Aldrich, Madrid, Spain) was used as a
control of protein loading. Protein expression levels
were determined by densitometry of the bands using
Image J software. Measurements were expressed as
arbitrary units and the results were normalized for
-actin. The numerical data were statistically analyzed
using ANOVA test.
In gel zymography
Gelatinolytic activity of MMP2 was measured
with in gel zymography assay following a protocol
adapted from one previously described [14]. Briefly,
60 mg of entorhinal cortex from MA, ADI/II-0, and
ADIII/IV-A cases was homogenized in Lysis buffer
(50 mM Tris-HCl pH 7.6, 150 mM NaCl, 5 mM CaCl2,
0.5% Triton, 0.05% Brij-35) along with 1 mM PMSF
and protease inhibitors, and left for 30 min in agitation
at 4◦C. The supernatant was collected by centrifugation
at 10,000 × g for 10 min and the total amount of protein
was quantified with BCA method. The same amount
of protein from each case was incubated with 50 l
of gelatin-Sepharose 4B (Pharmacia Biotech, Uppsala,
Sweden) for 1 h with constant shaking at 4◦C. After
centrifugation, the gelatin sepharose pellet was washed
twice with lysis buffer and then incubated with Elu-
tion buffer (lysis buffer plus 10% DMSO) for 30 min
in agitation at 4◦C. 30 l of the eluted material con-
taining gelatinases was mixed with an equal volume
of 2X sample buffer pH 6.8 and run at 30 mA in a
10% SDS-PAGE gel containing 0.1% gelatin. After
running, the gel was washed twice with 2.5% Triton
for 20 min, equilibrated for 15 min in the activity buffer
(50 mM Tris-HCl pH 7.5, 10 mM CaCl2, 0.025 NaN3)
and finally incubated in the same buffer for 20 h. The
gel was then stained for 1 h with 0.5% Coomassie bril-
liant blue in 40% methanol and 10% acetic acid, and
destained until bands clearly appeared. The bands cor-
responding to the proteolytic activity of MMP2 were
quantified using the Image J software and the data cor-
responding to MA and AD and cases were statistically
analyzed using ANOVA test.
Double-labeling immunofluorescence and
confocal microscopy
5 l-thick sections from entorhinal cortex were first
de-waxed and then stained with a saturated solution of
Sudan black for 10 min to block the autofluorescence
of lipofuscin. After one wash in 70% ethanol and sev-
eral in distilled water, the sections were blocked for
1 h with 10% fetal bovine serum (FBS) in PBS and
incubated overnight at 4◦C with 1% FBS/PBS solu-
tion containing a combination of mouse anti-MMP2
(Abcam, Clone 4D3, Cambridge, UK) and rabbit anti-
Tau-Thr181 (Calbiochem, Barcelona, Spain) primary
antibodies used at 1:50 and 1:100 dilutions, respec-
tively. After washing with PBS, the sections were
incubated for 45 min in the dark at room temper-
ature with a cocktail of Alexa488 anti-mouse and
Alexa555 anti-rabbit secondary antibodies at a dilu-
tion of 1:400 in the same vehicle solution of primary
antibodies. Nuclei were stained with DRAQ5 (Molec-
ular Probes, Oregon, USA) diluted 1:2,000 for 10 min.
Some sections were incubated only with the sec-
ondary antibodies. In addition, some samples were
pre-incubated with recombinant MMP2 previously
boiled to expose the antibody epitopes. The antigen-
antibody mixture was made at 10:1 ratio in PBS and left
overnight at 4◦C with gentle shaking. Sections from
the same individual were then incubated with either
MMP2 antibody alone or pre-absorbed MMP2 anti-
body in a parallel experiment. After washing in PBS,
the sections were finally mounted in Immuno-Fluore
Mounting medium (ICN Biomedicals), sealed, and
dried overnight. Sections were examined with a Leica
TCS-SL confocal microscope. Sections pre-incubated
with the antigenic peptide and sections incubated only
with the secondary antibodies were negative.
Cleavage of recombinant tau by MMP2
Full-length MMP2 (Sigma) was diluted to
a final concentration of 100 g/ml and acti-
vated through its incubation with 1 mM APMA
(4-aminophenylmercuric acetate) (Sigma) for 1 h at
37◦C. Afterwards, 2 g of the longest form of recom-
binant tau, which includes exons 2 and 3, and four
microtubules-binding repeats (T40) (r-peptide) were
incubated with 50 ng, 200 ng, and 500 ng of activated
MMP2 in a buffer containing 50 mM Tris-HCl pH 7.5,
10 mM CaCl2, and 150 mM NaCl. The reaction was
left at 37◦C for 3 h and then stopped by the addition of
Laemmli SDS sample buffer and followed by boiling.
The samples were subjected to 12% SDS-PAGE and
the tau proteolytic profile was visualized first on silver
staining (Amersham) and then by immunoblotting
with both N-terminal tau (Millipore) and Tau 46
C-terminal (Abcam) antibodies diluted 1:1,000.
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Fig. 1. Immunoblots of entorhinal cortex homogenates of (n = 5) AD cases stages I/II-0 (left panel); (n = 6) AD cases stages III/IV-A (right
panel) and (n = 5) middle-aged (MA) cases with no AD-related pathology are incubated with antibodies to MMP2. Western blot densitometry
(B) shows increment of MMP2 expression in ADI/II-0 (∗p = 0.021) and ADIII/IV-A (∗∗p = 0.0027) compared to MA subjects. Data values of
MMP2 were normalized to -actin. Open circle and triangles show values of individual cases. Filled shapes indicate mean ± SD.
PHF cleavage by MMP2
Paired helical filaments (PHFs) made of hyperphos-
phorylated tau were extracted as previously described
[19]. The samples were incubated with or without
E. coli alkaline phosphatase (18 Units/ml, Sigma) at
68◦C for 3 h. After this treatment, half of the sample
was incubated with 500 ng of activated MMP2 at 37◦C
for 3 h. The reaction was stopped by adding Laemmli
SDS sample buffer followed by boiling. The other half
was immediately mixed with Laemmli SDS sample
buffer and boiled. The samples were subjected to 12%
SDS-PAGE and immunoblotted with N-terminal tau
and Tau46 C-terminal antibodies.
RESULTS
Levels of MMP2 are increased in entorhinal
cortex at early stages of AD-related pathology
Total homogenates from entorhinal cortex from
MA, ADI/II-0, and ADIII/IV-A cases were run in
SDS-PAGE gels and immunoblotted with antibodies
recognizing full-length MMP2 (gelatinase A). The
monoclonal antibody for MMP2 revealed an increment
of this protein in ADI/II-0 and ADIII/IV-A with respect
to MA cases (Fig. 1A, B; Supplementary Fig. 1). Values
of MMP2 were normalized to -actin; ANOVA test,
used to compare the AD groups with MA group, pro-
duced p-values for ADI/II-0 and ADIII/IV-A of 0.021
and 0.0027, respectively.
To further investigate the possible alteration of this
metalloprotein at early stages of AD-related pathol-
ogy, MMP2 was isolated from entorhinal cortex. The
gelatin zymography assay showed one typical band of
72 kDa corresponding to MMP2 (Fig. 2). A significant
increase in MMP2 gelatinolytic activity was observed
in ADI/II-0 (p = 0.007) and ADIII/IV-A (p = 0.008)
groups with respect to MA cases with no AD-related
pathology (Fig. 2A, B), in agreement with the differ-
ence in MMP2 expression levels shown by western
blot.
Immuno-co-localization of MMP2 with tau lesions
in the entorhinal cortex at early stages of
AD-related pathology
MMP2 is weakly expressed in neurons in the normal
brain; however, MMP2 appears to accumulate in neu-
rons containing NFTs in AD. Sections of entorhinal
cortex of AD and MA cases were double stained with
anti-MMP2 and anti-phosphoTau-Thr181 antibodies
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Fig. 2. Gelatinases are isolated from entorhinal cortex of ADI/II-0 (A), ADIII/IV-A (B), and middle-aged (MA) cases using gelatin sepharore 4B,
and then separated in 10% SDS-PAGE gel containing 0.1% gelatin. The figure represents the negative image of the zymography gel showing a
band of 72 kDa corresponding to MMP2. A significant increase in MMP2 expression levels is seen in ADI/II-0 (n = 5; p = 0.007) and ADIII/IV-A
(n = 5, p = 0.008) with respect to MA cases (n = 5). Open circle and triangles show values of individual cases. Filled shapes indicate mean ± SD.
in order to study the distribution of the metallopro-
teinase with respect to the tau lesions (Fig. 3). MMP2
co-localizes with Tau-Thr181 in some NFTs and dys-
trophic neurites in cases with AD-related pathology.
MMP2 cleaves recombinant tau at C-terminal
region
Full-length tau 4R (Tau40) was incubated with
increasing concentrations of recombinant active
MMP2 for 3 h at 37◦C. The pattern of tau cleavage
was analyzed in 12% SDS-PAGE and the proteolysis
bands were visualized with silver staining (Fig. 4A). A
gradual increase in MMP2 concentrations from 50 ng
to 500 ng reduced the intensity of the 55 kDa band,
corresponding to full-length tau (lane 1), while low
molecular weight bands, resulting from tau cleavage,
appeared in a dose-dependent manner (lanes 2–4). At
the lowest concentration assayed (50 ng MMP2), three
major bands of 35, 30, and 25 kDa were observed, but
the band at 30 kDa become much more intense and
new low molecular weight bands ranging from 25 to
10 kDa appeared at higher concentrations of MMP2.
In order to validate tau cleavage by MMP2, the
proteolytic bands were visualized with immunoblot-
ting using N-terminal or C-terminal tau antibodies
(Fig. 4B). The N-terminal antibody raised against the
first 16 amino acids of tau showed a band of 55 kDa
corresponding to full-length tau and several proteolytic
bands between 40 and 30 kDa corresponding to trun-
cated tau (Fig. 4B left, lane 1). Incubation with 200 ng
and 500 ng of MMP2 reduced the expression of the
upper bands and resulted in the appearance of inter-
mediate bands of about 35 kDa and below 20 kDa
(Fig. 4B left, lanes 3, 4). Additionally, immunoblotting
with the C-terminal tau antibody showed some bands,
ranging between 37 and 25 kDa, which were present
in the baseline samples and after incubation with 50 ng
MMP2. Incubation with higher doses of MMP2 abol-
ished C-terminal immunoreactivity thus indicating that
major cleavage of tau occurs at the C-terminal domain.
(Fig. 4B, right, comparing lanes 1, 2 with lanes 3
and 4).
Lack of proteolysis of PHF tau by MMP2
To further investigate whether MMP2 had an effect
on tau aggregates in vivo, we analyzed MMP2 degra-
dation of PHF-tau extracted from AD brains. Samples
were analyzed with western blot using phospho-tau
AT8 antibody and N-terminal and C-terminal (Tau46)
antibodies (Fig. 5A, B, C, respectively). PHF-tau
was treated either with or without E. coli alkaline
phosphatase to obtain dephosphorylated and phos-
phorylated PHF-tau samples. Typical bands of 68
kDa, 64 kDa, and 60 kDa [19] together with a
higher band of 73 kDa and several bands of low
molecular weight, corresponding to truncated tau
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Fig. 3. Immunofluorescence and confocal microscopy of entorhinal cortex (layer II) of middle aged (MA) (A-C), ADI/II-0 (D-F), and ADIII/IV-A
(G-I) cases show MMP2 immunoreactivity in neurons with NFTs (arrows) and some dystrophic neurites (arrowhead) in ADI/II-0 and ADIII/IV-A.
A, D, G (green): MMP2 antibody; B, E, H (red): anti Tau-Thr181 antibody; C, F, I: merge. L-O: Detail of MMP2-Tau co-localization in tangles
of cases of ADI/II-0 (L, M) and ADIII/IV-A (N, O).
species, were found in non-treated samples (not sub-
jected to dephosphorylation Fig. 5A, in all panels).
No signal of phospho-tau protein was seen in the
dephosphorylated sample using the AT8 antibody
(Fig. 5A; lane B).
Several bands ranging between 70 and 50 kDa
were observed instead following tau dephosphory-
lation (Fig. 5B, C; lanes B). Samples of PHF-tau
treated either with or without E. coli phosphatase
were then incubated with MMP2. Immunoblots with
N-terminal and C-terminal (Tau46) antibodies did
not show any difference in the degradation pattern
between MMP2-non-incubated and MMP2-incubated
samples independently of the phosphorylation state
of tau (Fig. 5B, C; lanes C, D). No additional PHF
cleavage by MMP2 was observed in phosphorylated
or dephosphorylated samples even at high exposition
time of the membrane (Fig. 5B, C).
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Fig. 4. A) MMP2 cleaves recombinant tau in a dose-dependent manner. MMP2 concentration from 50 ng to 200 ng and 500 ng (lanes 2, 3, and
4, respectively) reduces the intensity of the 55 kDa band corresponding to full-length tau. Low molecular weight bands appear following tau
incubation with increasing concentrations of MMP2; silver staining. B) Immunoblotting with antibodies against N-terminal tau and C-terminal
tau (Tau46) shows that incubation of recombinant tau with MMP2 results in reduced levels of full-length tau and in the appearance of bands
of lower molecular weight revealed with N-terminal tau antibody. In contrast, no lower bands appear with C-terminal tau antibody following
incubation of recombinant tau with 200 ng and 500 ng of MMP2. Lane 1: tau alone; lanes 2, 3, 4: tau incubated with 50 ng, 200 ng, and 500 ng
of MMP2, respectively.
Fig. 5. PHF-tau was extracted from AD cases and half of the sample was treated with E. coli alkaline phosphatase (lanes B and D) while the other
half was not subjected to phosphatase treatment (lanes A and C). Samples were analyzed with western blot using phospho-tau AT8 antibody,
N-terminal and C-terminal (Tau46) antibodies (A, B, and C, respectively). Samples without alkaline phosphatase pre-treatment showed the
typical AD tau pattern of 68 kDa, 64 kDa, and 60 kDa bands together with several bands of lower molecular weight corresponding to truncated
tau. This pattern is best visualized with short incubation time as seen with AT8 antibody (A, lane A). Longer incubation time, as employed
with anti-N-terminal and C-terminal antibodies, results in a blurred band due to overexposure (B and C, lanes A, asterisk). Yet overexposure
is needed to better visualize the effects of MMP2 incubation (lanes C and D). Hyperphosphorylated tau band pattern is modified following
pre-treatment with alkaline phosphatase: no bands are seen using AT8 antibody (A, lane B), whereas several bands ranging between 70 and 50
kDa are identified with N-terminal and C-terminal antibodies. (B and C, lanes B; double asterisk). Immunoblots with N-terminal and C-terminal
(Tau46) antibody show no modifications of the profile of tau bands, following incubation with MMP2 (B and C; lanes C, D).
DISCUSSION
The present study, using western blotting and gelatin
zymography, shows increased expression levels of
MMP2 at early (Braak and Braak I/II-0) and middle
(Braak and Braak III/IV-A) stages of AD-related
pathology compared with middle-aged cases with no
AD-related pathology. Since the mean age in MA cases
was lower than in cases with AD-related pathology,
it can be suggested that increased MMP2 expression
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levels might be the effect of aging rather than the
effect of AD pathology. However, MMP2 was found in
some neurons with NFTs and in dystrophic neurites,
co-localizing with hyperphosphorylated tau, as visu-
alized with double-labeling immunofluorescence and
confocal microscopy, thus indicating a close relation-
ship between MMP2 and hyper-phosphorylated tau in
AD.
Proteolysis of tau contributes to tangle formation
[20–22]. An important fraction of tau in fibrils is
truncated at positions Glu-391 and Asp-421, and tau
is cleaved at Asp-421 by caspases [23]. Removal of
the C-terminal domain of tau enhances nucleation
and fibrillization reactions in vitro [24]. Moreover,
time-course analysis and antibody labeling of tau inclu-
sions demonstrates that tau oligomers appear early in
the AD pathogenesis and are the toxic form of tau,
as they are able to inhibit axonal transport in neu-
rons and are involved in synapse and neuron loss
[25–27].
So far, MMPs have always been considered to be
only extracellular degrading enzymes, and their sub-
strates have always been identified in proteins of the
extracellular matrix. However, MMP2 has intracel-
lular proteolytic activity in variegated pathological
conditions such as tumor growth and heart and brain
ischemia [28]. MMP9 is able to cleave tau at N- and
C-terminal regions, thus liberating the hexapeptide
domain of the protein and facilitating tau aggregation
[17]. The present study demonstrates that MMP2 is
able to cleave tau in vitro after co-incubation of recom-
binant full-length tau with MMP2; western blotting
further shows that tau fragments are likely generated
at the C-terminal region of the protein. Based on these
evidences, overexpression of MMP2 in ADI/II and
ADIII/IV at neurofibrillary lesions, may suggest a role
of MMP2 in the promotion of tau fibrillization.
It may also be suggested that MMP2 has physiolog-
ical functions in normal tau proteolysis whatever tau
degradation occurs in the extracellular space or in the
cytoplasm of neurons.
Thrombin and pro-thrombin are found in NFTs,
dystrophic neurites, and reactive microglia [29], thus
suggesting that they may be involved in tau proteol-
ysis. However, increased tau phosphorylation inhibits
this process, and PHFs are more resistant to thrombin
cleavage [30] in the same line as we can here observed
for MMP2. We can then conclude that upregulation
of MMP2 at early and middle stages of AD-related
pathology may be an additional mechanism which pro-
mote tau fibrillization. Moreover, the incapacity of
MMP2 to degrade hyperphosphorylated tau in paired
helical filaments may further contribute to the accumu-
lation of tau aggregates.
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